MORF-057 is under clinical development by Morphic Therapeutic and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase II drugs for Ulcerative Colitis have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MORF-057’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MORF-057 is under development for the treatment of autoimmune disorders including ulcerative colitis, Crohn's disease and eosinophilic esophagitis. It is administered orally. It is developed based on Morphic integrin technology (MInT). The drug candidate acts by targeting integrin alpha 4 and beta 7.
Morphic Therapeutic overview
Morphic Therapeutic Inc is a biotechnology firm. Oral integrin medicines are developed by the firm. The company is headquartered in United States.
For a complete picture of MORF-057’s drug-specific PTSR and LoA scores, buy the report here.